(VIANEWS) – The NASDAQ opens in less than three hours and 10x Genomics‘s pre-market value is already 4.92% down.
10x Genomics’s last close was $51.61, 38.55% below its 52-week high of $83.99.
The last session, NASDAQ finished with 10x Genomics (TXG) jumping 0.35% to $51.61. NASDAQ dropped 0.58% to $11,787.27, after two sequential sessions in a row of losses, on what was a somewhat down trend trading session.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Earnings Per Share
As for profitability, 10x Genomics has a trailing twelve months EPS of $-4.17.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.22%.
Volume
Today’s last reported volume for 10x Genomics is 1314680 which is 14.95% above its average volume of 1143610.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 93.8% and positive 7.9% for the next.
More news about 10x Genomics (TXG).
